Repurposing Anticancer Drugs Targeting the MAPK/ERK Signaling Pathway for the Treatment of Respiratory Virus Infections
International Journal of Molecular Sciences · 25.06.2024 · 25 (13) · 6946
DOI: 10.3390/ijms25136946 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.06.2024. Verfasst von Yuchen Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Medical Department, Queen Mary School, Nanchang University, Nanchang 330031, China. Hauptthemen laut MEDLINE: Drug Repositioning, MAP Kinase Signaling System, Respiratory Tract Infections. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Respiratory virus infections remain a significant challenge to human health and the social economy. The symptoms range from mild rhinitis and nasal congestion to severe lower respiratory tract dysfunction and even mortality. The efficacy of therapeutic drugs targeting respiratory viruses varies, depending upon infection time and the drug resistance engendered by a high frequency of viral genome mutations, necessitating the development of new strategies. The MAPK/ERK pathway that was well delineated in the 1980s represents a classical signaling cascade, essential for cell proliferation, survival, and differentiation. Since this pathway is constitutively activated in many cancers by oncogenes, several drugs inhibiting Raf/MEK/ERK have been developed and currently used in anticancer treatment. Two decades ago, it was reported that viruses such as HIV and influenza viruses could exploit the host cellular MAPK/ERK pathway for their replication. Thus, it would be feasible to repurpose this category of the pathway inhibitors for the treatment of respiratory viral infections. The advantage is that the host genes are not easy to mutate such that the drug resistance rarely occurs during short-period treatment of viruses. Therefore, in this review we will summarize the research progress on the role of the MAPK/ERK pathway in respiratory virus amplification and discuss the potential of the pathway inhibitors (MEK inhibitors) in the treatment of respiratory viral infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Department, Queen Mary School, Nanchang University, Nanchang 330031, China.
ORCID-Profile: Zhijun Luo
Zitieren
APA
Liu, Y., & Luo, Z. (2024). Repurposing Anticancer Drugs Targeting the MAPK/ERK Signaling Pathway for the Treatment of Respiratory Virus Infections. International Journal of Molecular Sciences, 25(13), 6946. https://doi.org/10.3390/ijms25136946
Vancouver
Liu Y, Luo Z. Repurposing Anticancer Drugs Targeting the MAPK/ERK Signaling Pathway for the Treatment of Respiratory Virus Infections. International Journal of Molecular Sciences. 2024;25(13):6946. doi:10.3390/ijms25136946
BibTeX
@article{Liu2024,
author = {Liu, Yuchen and Luo, Zhijun},
title = {Repurposing Anticancer Drugs Targeting the MAPK/ERK Signaling Pathway for the Treatment of Respiratory Virus Infections},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {13},
pages = {6946},
doi = {10.3390/ijms25136946}
}
EUVIMED